Tyra Biosciences, Inc. 8-K

What Happened

• Tyra Biosciences, Inc. filed an 8-K on April 17, 2026 reporting that on April 16, 2026 the board approved increasing the number of authorized directors from nine to ten and appointed Habib J. Dable as a Class II director. His initial term expires at the Company’s 2026 annual meeting of stockholders.
• Mr. Dable, age 56, is an advisor at RA Capital Management (since April 2022) and was previously President & CEO of Acceleron Pharma (Dec 2016–Nov 2021). He has held senior roles at Bayer and serves or has served on multiple biopharma boards.

Key Details

• Board change: increased authorized directors from 9 to 10; appointment effective April 16, 2026.
• New director: Habib J. Dable (56), advisor at RA Capital; former CEO of Acceleron Pharma (Dec 2016–Nov 2021); prior senior roles at Bayer.
• Compensation: granted options to purchase 44,400 shares of common stock (exercise price = fair market value on grant date); options vest in substantially equal monthly installments over 36 months. He will also receive cash board/committee fees per the Company’s Non-Employee Director Compensation Program.
• Governance: Mr. Dable entered the Company’s standard indemnification agreement and was determined by the Board to be an independent director under Nasdaq rules. The filing reports no related-party transactions subject to disclosure.

Why It Matters

• The appointment adds an experienced biopharma executive and board member to Tyra’s governance team, which may strengthen industry, development and commercial experience at the board level.
• For investors, the concrete impacts are: the board size increases to 10, and the company issued options for 44,400 shares to the new director (a potential source of future share issuance if exercised).
• The Board’s determination of independence and the use of standard compensation and indemnification arrangements indicate this is a non-employee director appointment focused on governance rather than executive management.